Document is current
Any future updates will be listed below
-
Authors
Gruber, Joshua J. https://orcid.org/0000-0002-8642-6074
Afghahi, Anosheh
Timms, Kirsten
DeWees, Alyssa
Gross, Wyatt
Aushev, Vasily N.
Wu, Hsin-Ta
Balcioglu, Mustafa
Sethi, Himanshu
Scott, Danika
Foran, Jessica
McMillan, Alex
Ford, James M.
Telli, Melinda L. https://orcid.org/0000-0001-7993-1235
-
Funding
Funding for this research was provided by:
Jane Coffin Childs Memorial Fund for Medical Research
Susan G. Komen (PDF17483383, PDF15331052)
Breast Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA245024)
Pfizer
- License Information
-
More Information
Article History
Received: 14 August 2021
Accepted: 29 August 2022
First Online: 17 October 2022
Competing interests
: J.J.G. had contracted research with Curis, consults for Sharma Therapeutics, LLC and Guidepoint and reports research support (to his institution) from Hummingbird Biosciences. J.M.F. has received research support (to his institution) from AstraZeneca, Genentech, Incyte, Merus, Pfizer and PUMA. M.L.T. reports research support (to her institution) from AbbVie, Arvinas, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GlaxoSmithKline, Hummingbird Biosciences, Medivation, Merck, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro and Vertex and consulting/advisory fees from AbbVie, Aduro Biotech, AstraZeneca, Blueprint Medicines, Celgene, Daiichi Sankyo, Genentech/Roche, Gilead, GlaxoSmithKline, G1 Therapeutics, Guardant, Immunomedics, Lilly, Merck, Natera, Novartis, OncoSec, Pfizer, RefleXion and Sanofi. Funding support was provided by Pfizer in the form of an unrestricted research grant for drug and clinical trial budget. V.N.A., H.W., M.B. and H.S. are full-time employees of Natera with stock or options to own stock in the company. K.T. is an employee and shareholder of Myriad Genetics. The remaining authors declare no competing interests.
